NCT06380647|CompletedDMC
Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns
childburn
Loading search results
childburn
Sponsor study identifier
interventional
64
1 country
1
Study Start
October 1, 2019
Actual (reported)Primary Completion
September 30, 2020
Actual (reported)Study Completion
September 30, 2020
Actual (reported)Introduction: Early detection is important in treating patients with Eczema Herpeticum (EH), which may arise in paediatric burn patients. As soon as a clinical diagnosis is confirmed, antiviral medications should be started to ensure an early resolution of the disease. Several studies have indicated that acyclovir is the best treatment for EH lesions in the majority of individuals. Objective: Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 30, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2019
Actual (reported)September 30, 2020
Actual (reported)September 30, 2020
Actual (reported)March 31, 2024
Actual (reported)April 24, 2024
Actual (reported)Number of participants with positive Tzanck smear
Prophylactic acyclovir was compared with placebo regarding preventing eczema herpeticum prophylactically
1 year
Group A patients were given intra venous acyclovir at dosage of 5-10 mg/kg/day into three doses for 7-14 days during their stay.Giant smear testing was done from suspected lesion on burn area to confirm viral infection
Group B patients were given intravenous normal saline 5-10 mg/kg into three doses as placebo for 7 to 14 days,Giant smear testing was done from suspected lesion on burn area to confirm viral infection
Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
department of pediatric surgery King Edward Medical University
Lahore, Punjab Province, 54000, Pakistan
Muhammad Sharif
King edward Medical University/Mayo Hospital Lahore
64 participants (actual enrollment reported by the registry).
First Submitted
March 31, 2024
First Posted
April 24, 2024
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Contact the study team to confirm eligibility.
Study Start
October 1, 2019
Actual (reported)Primary Completion
September 30, 2020
Actual (reported)Study Completion
September 30, 2020
Actual (reported)Last Updated
April 24, 2024
Record last verified: 2024-04
will be shared on request
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: